{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:57:58Z","timestamp":1770433078190,"version":"3.49.0"},"reference-count":56,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:p>OBJECTIVES. The goals were to describe the management of multidrug-resistant tuberculosis among children, to examine the tolerability of second-line antituberculosis agents among children, and to report the outcomes of children treated for multidrug-resistant tuberculosis in poor urban communities in Lima, Peru, a city with high tuberculosis prevalence.<\/jats:p>\n               <jats:p>METHODS. A retrospective analysis of data for 38 children &amp;lt;15 years of age with multidrug-resistant tuberculosis, either documented with drug sensitivity testing of the child's tuberculosis isolate or suspected on the basis of the presence of clinical symptoms for a child with a household contact with documented multidrug-resistant tuberculosis, was performed. All 38 children initiated a supervised individualized treatment regimen for multidrug-resistant tuberculosis between July 1999 and July 2003. Each child received 18 to 24 months of therapy with \u22655 first- or second-line drugs to which their Mycobacterium tuberculosis strain was presumed to be sensitive.<\/jats:p>\n               <jats:p>RESULTS. Forty-five percent of the children had malnutrition or anemia at the time of diagnosis, 29% had severe radiographic findings (defined as bilateral or cavitary disease), and 13% had extrapulmonary disease. Forty-five percent of the children were hospitalized initially because of the severity of illness. Adverse events were observed for 42% of the children, but no events required suspension of therapy for &amp;gt;5 days. Ninety-five percent of the children (36 of 38 children) achieved cures or probable cures, 1 child (2.5%) died, and 1 child (2.5%) defaulted from therapy.<\/jats:p>\n               <jats:p>CONCLUSIONS. Multidrug-resistant tuberculosis disease among children can be treated successfully in resource-poor settings. Treatment is well tolerated by children, and severe adverse events with second-line agents are rare.<\/jats:p>","DOI":"10.1542\/peds.2005-2235","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T23:20:51Z","timestamp":1149204051000},"page":"2022-2029","source":"Crossref","is-referenced-by-count":65,"title":["Community-Based Therapy for Children With Multidrug-Resistant Tuberculosis"],"prefix":"10.1542","volume":"117","author":[{"given":"Peter C.","family":"Drobac","sequence":"first","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joia S.","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Socios en Salud Sucursal Peru, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Keith","family":"Joseph","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Furin","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Department of Social Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herna\u0301n","family":"del Castillo","sequence":"additional","affiliation":[{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Instituto de Salud del Nin\u0303o, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya S.","family":"Shin","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Department of Social Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes C.","family":"Becerra","sequence":"additional","affiliation":[{"name":"Social Medicine and Health Inequalities"},{"name":"Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Partners in Health, Boston, Massachusetts"},{"name":"Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,6,1]]},"reference":[{"key":"2021120822595403300_R1","unstructured":"World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2004. Geneva, Switzerland: World Health Organization; 1999"},{"key":"2021120822595403300_R2","doi-asserted-by":"crossref","unstructured":"Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med.\u20082003;163:1009\u20131021","DOI":"10.1001\/archinte.163.9.1009"},{"key":"2021120822595403300_R3","unstructured":"World Health Organization. Anti-Tuberculosis Drug Resistance in the World: 3rd Report: The WHO\/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999\u20132002. Geneva, Switzerland: World Health Organization; 2004"},{"key":"2021120822595403300_R4","unstructured":"Schaaf HS, Gie RP, Beyers N, et al. Primary drug-resistant tuberculosis in children. Int J Tuberc Lung Dis.\u20082000;4:1149\u20131155"},{"key":"2021120822595403300_R5","unstructured":"Kassa-Kelembho E, Bobossi-Serengbe G, Takeng EC, et al. Surveillance of drug-resistant childhood tuberculosis in Bangui, Central African Republic. Int J Tuberc Lung Dis.\u20082004;8:574\u2013578"},{"key":"2021120822595403300_R6","doi-asserted-by":"crossref","unstructured":"Sun SJ, Bennett DE, Flood J, et al. Identifying the sources of tuberculosis in young children: a multistate investigation. Emerg Infect Dis.\u20082002;8:1216\u20131223","DOI":"10.3201\/eid0811.020419"},{"key":"2021120822595403300_R7","unstructured":"Steiner P, Rao M. Drug-resistant tuberculosis in children. Semin Pediatr Infect Dis.\u20081993;4:275\u2013282"},{"key":"2021120822595403300_R8","doi-asserted-by":"crossref","unstructured":"Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in six countries. JAMA.\u20082000;283:2537\u20132545","DOI":"10.1001\/jama.283.19.2537"},{"key":"2021120822595403300_R9","doi-asserted-by":"crossref","unstructured":"Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation: initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis.\u20081990;142:1301\u20131305","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1301"},{"key":"2021120822595403300_R10","unstructured":"Kimmerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis.\u20081999;3:451\u2013453"},{"key":"2021120822595403300_R11","unstructured":"Farmer PE, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis.\u20081998;2:869\u2013876"},{"key":"2021120822595403300_R12","unstructured":"Peru Ministry of Health. Surveillance of Antituberculosis Drug Resistance in Peru, 1999 [in Spanish]. Lima, Peru: Tuberculosis Control Program, National Institute of Health (Peru); 2000"},{"key":"2021120822595403300_R13","doi-asserted-by":"crossref","unstructured":"Shin S, Furin J, Bayona J, et al. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med.\u20082004;59:1529\u20131539","DOI":"10.1016\/j.socscimed.2004.01.027"},{"key":"2021120822595403300_R14","doi-asserted-by":"crossref","unstructured":"Farmer PE, Kim JY. Community based approaches to the control of multidrug-resistant tuberculosis: introducing \u201cDOTS-Plus. \u201d BMJ.\u20081998;317:671\u2013674","DOI":"10.1136\/bmj.317.7159.671"},{"key":"2021120822595403300_R15","unstructured":"Farmer PE, Kim JY, Mitnick C, Timperi R. Responding to outbreaks of MDRTB: introducing \u201cDOTS-Plus.\u201d In: Reichmaan LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2000:447\u2013469"},{"key":"2021120822595403300_R16","doi-asserted-by":"crossref","unstructured":"Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med.\u20082003;348:119\u2013128","DOI":"10.1056\/NEJMoa022928"},{"key":"2021120822595403300_R17","doi-asserted-by":"crossref","unstructured":"Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med.\u20081995;333:907\u2013911","DOI":"10.1056\/NEJM199510053331404"},{"key":"2021120822595403300_R18","doi-asserted-by":"crossref","unstructured":"Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994\u20131997. Chest.\u20082001;120:343\u2013348","DOI":"10.1378\/chest.120.2.343"},{"key":"2021120822595403300_R19","doi-asserted-by":"crossref","unstructured":"Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med.\u20082001;345:170\u2013174","DOI":"10.1056\/NEJM200107193450303"},{"key":"2021120822595403300_R20","unstructured":"Geerligs WA, van Altena R, de Lange WMC, Sooligen TS, ven der Werf TS. Multidrug resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis.\u20082000;4:758\u2013764"},{"key":"2021120822595403300_R21","doi-asserted-by":"crossref","unstructured":"Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin\/levofloxacin-containing regimens. Chest.\u20082000;117:744\u2013751","DOI":"10.1378\/chest.117.3.744"},{"key":"2021120822595403300_R22","unstructured":"Starke JR. Tuberculosis in childhood and pregnancy. In: Friedman LN, ed. Tuberculosis: Current Concepts and Treatment. 2nd ed. Boca Raton, FL: CRC Press; 2000:191\u2013229"},{"key":"2021120822595403300_R23","unstructured":"Hessling AC, Schaaf HS, Gie RP, et al. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis.\u20082002;6:1038\u20131045"},{"key":"2021120822595403300_R24","doi-asserted-by":"crossref","unstructured":"Schluger NW, Lawrence RM, McGuiness G, et al. Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Pediatr Pulm.\u20081996;21:138\u2013142","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<138::AID-PPUL9>3.0.CO;2-N"},{"key":"2021120822595403300_R25","doi-asserted-by":"crossref","unstructured":"de Charnace G, Delacourt C. Diagnostic techniques in paediatric tuberculosis. Paediatr Respir Rev.\u20082001;2:120\u2013125","DOI":"10.1053\/prrv.2000.0119"},{"key":"2021120822595403300_R26","doi-asserted-by":"crossref","unstructured":"Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for better methods. Emerg Infect Dis.\u20081995;1:115\u2013123","DOI":"10.3201\/eid0104.950402"},{"key":"2021120822595403300_R27","unstructured":"Snider DE, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis.\u20081985;132:125\u2013132"},{"key":"2021120822595403300_R28","unstructured":"Mukherjee JS, Joseph KJ, Rich ML, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients in Lima, Peru. Int J Tuberc Lung Dis.\u20082003;7:637\u2013644"},{"key":"2021120822595403300_R29","unstructured":"Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis.\u20082003;7(suppl 3):S501\u2013S509"},{"key":"2021120822595403300_R30","doi-asserted-by":"crossref","unstructured":"Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet.\u20082004;363:474\u2013481","DOI":"10.1016\/S0140-6736(04)15496-2"},{"key":"2021120822595403300_R31","unstructured":"Partners in Health. DOTS-Plus Handbook: Guide to the Community-Based Treatment of MDR-TB. Boston, MA: Partners in Health; 2002. Available at: www.pih.org. Accessed May 13, 2005"},{"key":"2021120822595403300_R32","doi-asserted-by":"crossref","unstructured":"Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis control. Science.\u20082001;293:1049\u20131051","DOI":"10.1126\/science.1061861"},{"key":"2021120822595403300_R33","doi-asserted-by":"crossref","unstructured":"Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health.\u20082002;7:970\u2013976","DOI":"10.1046\/j.1365-3156.2002.00960.x"},{"key":"2021120822595403300_R34","unstructured":"Graham SM, Gie RP, Schaaf HS, et al. Childhood tuberculosis: clinical research needs. Int J Tuberc Lung Dis.\u20082004;8:648\u2013657"},{"key":"2021120822595403300_R35","unstructured":"Gupta R, Espinal M, Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritized research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis.\u20082003;7:410\u2013414"},{"key":"2021120822595403300_R36","doi-asserted-by":"crossref","unstructured":"Pavlopoulou ID, Theodoridou M, Daikos GL, et al. Drug-resistant tuberculous mastoiditis in 2 children. Scand J Infect Dis.\u20082000;32:436\u2013438","DOI":"10.1080\/003655400750045105"},{"key":"2021120822595403300_R37","doi-asserted-by":"crossref","unstructured":"Lindquist SW, Steinmetz BA, Starke JR. Multidrug-resistant tuberculosis of the first cervical vertebra in an immunocompetent adolescent. Pediatr Infect Dis J.\u20081997;16:333\u2013335","DOI":"10.1097\/00006454-199703000-00020"},{"key":"2021120822595403300_R38","unstructured":"Mehta JB, Mejia E, Gallemore GH, Ramsey GF. Drug-resistant tuberculosis of the brain in a two-year-old child. Tenn Med.\u20081998;91:285\u2013287"},{"key":"2021120822595403300_R39","doi-asserted-by":"crossref","unstructured":"Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child.\u20082003;88:1106\u20131111","DOI":"10.1136\/adc.88.12.1106"},{"key":"2021120822595403300_R40","doi-asserted-by":"crossref","unstructured":"van Oud-Alblas HJB, van Vliet ME, Kimpen JLL, de Villiers GS, Schaaf HS, Donald PR. Human immunodeficiency virus infection in children hospitalized with tuberculosis. Ann Trop Paediatr.\u20082002;22:115\u2013123","DOI":"10.1179\/027249302125000832"},{"key":"2021120822595403300_R41","doi-asserted-by":"crossref","unstructured":"Furin JJ, Becerra MC, Shin SS, et al. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis.\u20082000;19:132\u2013136","DOI":"10.1007\/s100960050445"},{"key":"2021120822595403300_R42","doi-asserted-by":"crossref","unstructured":"Campos PE, Suarez PG, Sanchez J, et al. Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg Infect Dis.\u20082003;9:1571\u20131578","DOI":"10.3201\/eid0912.020731"},{"key":"2021120822595403300_R43","doi-asserted-by":"crossref","unstructured":"Curtis AB, Ridzon MD, Vogel BS, et al. Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med.\u20081999;341:1491\u20131495","DOI":"10.1056\/NEJM199911113412002"},{"key":"2021120822595403300_R44","unstructured":"Laszlo A. How accurate is drug susceptibility testing for second-line drugs: do we need a proficiency testing exercise?Int J Tuberc Lung Dis.\u20082002;6:S29"},{"key":"2021120822595403300_R45","doi-asserted-by":"crossref","unstructured":"Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug resistant tuberculosis. Pediatr Infect Dis J.\u20082000;19:695\u2013699","DOI":"10.1097\/00006454-200008000-00005"},{"key":"2021120822595403300_R46","doi-asserted-by":"crossref","unstructured":"Steiner P, Rao M, Mitchell M, et al. Primary drug-resistant tuberculosis in children: correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis. Am J Dis Child.\u20081985;139:780\u2013782","DOI":"10.1001\/archpedi.1985.02140100042023"},{"key":"2021120822595403300_R47","doi-asserted-by":"crossref","unstructured":"Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics.\u20082002;109:765\u2013771","DOI":"10.1542\/peds.109.5.765"},{"key":"2021120822595403300_R48","unstructured":"Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis.\u20082001;5:648\u2013655"},{"key":"2021120822595403300_R49","unstructured":"Shrpnack DD, Mastin JP, Childress CP, Henningsen GM. Quinolone arthropathy in New Zealand white rabbits. Lab Anim Sci.\u20081994;44:436\u2013442"},{"key":"2021120822595403300_R50","doi-asserted-by":"crossref","unstructured":"Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use: safety report. Pediatr Infect Dis J.\u20081997;16:127\u2013129","DOI":"10.1097\/00006454-199701000-00036"},{"key":"2021120822595403300_R51","unstructured":"Schaad UB, Stoupis C, Wedgwood J, Tschappeler H, Vock P. Clinical, radiologic and MR monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three month course of ciprofloxacin. Pediatr Infect Dis J.\u20081991;10:723\u2013729"},{"key":"2021120822595403300_R52","doi-asserted-by":"crossref","unstructured":"Redmond AO. Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J.\u20081997;16:147\u2013149","DOI":"10.1097\/00006454-199701000-00040"},{"key":"2021120822595403300_R53","doi-asserted-by":"crossref","unstructured":"Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J.\u20082003;22:1128\u20131132","DOI":"10.1097\/01.inf.0000101994.25947.12"},{"key":"2021120822595403300_R54","doi-asserted-by":"crossref","unstructured":"Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother.\u20082000;34:347\u2013359","DOI":"10.1345\/aph.18146"},{"key":"2021120822595403300_R55","doi-asserted-by":"crossref","unstructured":"Dagan R, Arguedas A, Schaad UB. Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J.\u20082004;23:390\u2013398","DOI":"10.1097\/01.inf.0000126272.08795.7a"},{"key":"2021120822595403300_R56","doi-asserted-by":"crossref","unstructured":"Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs.\u20081999;58:633\u2013661","DOI":"10.2165\/00003495-199958040-00005"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/6\/2022\/1072778\/zpe00606002022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/6\/2022\/1072778\/zpe00606002022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:59:29Z","timestamp":1639018769000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/6\/2022\/69443\/Community-Based-Therapy-for-Children-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2006,6,1]]},"published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-2235","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}